MiNK Therapeutics Reports Third Quarter Financial Results Exceeding Estimates
MiNK Therapeutics (INKT) reported third-quarter financial results that surpassed analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of -$0.50, which outperformed estimates by $0.16, while quarterly revenue reached $0.2 million, beating projections by $0.13 million. Regarding its liquidity position, MiNK Therapeutics ended the quarter with $7.5 million in cash and cash equivalents. This represents a decrease from the $8.8 million reported as of June 30, 2026.
Tickers: $INKT
Topics: cash position earnings beat revenue beat